AION Healthspan, Inc.

AION Healthspan, Inc. Clinical-stage biotechnology company, advancing regenerative medicine to improve healthy lifespan

If you or someone you know suffers from Diabetes Nephropathy or other forms of Chronic Kidney Disease, please share.
08/14/2025

If you or someone you know suffers from Diabetes Nephropathy or other forms of Chronic Kidney Disease, please share.

If you are living with Diabetes Nephropathy or other forms of Chronic Kidney Disease (Stage 3) you may qualify to join a...
06/11/2025

If you are living with Diabetes Nephropathy or other forms of Chronic Kidney Disease (Stage 3) you may qualify to join a novel cell therapy clinical research trial that does not require any anti-rejection drugs, with the objective to slow down or possibly even reverse disease, to prevent progression towards dialysis and kidney transplantation.

Diabetes Research Institute Foundation Camillo Ricordi The Cure Alliance American Society of Nephrology American Association of Kidney Patients National Kidney Foundation

www.AIONHealthspan.com

If you are living with Diabetes Nephropathy or other forms of Chronic Kidney Disease (Stage 3) you may qualify to join a...
06/11/2025

If you are living with Diabetes Nephropathy or other forms of Chronic Kidney Disease (Stage 3) you may qualify to join a novel cell therapy clinical research trial that does not require any anti-rejection drugs, with the objective to slow down or possibly even reverse disease, to prevent progression towards dialysis and kidney transplantation.

Diabetes Research Institute Foundation Camillo Ricordi The Cure Alliance American Society of Nephrology American Association of Kidney Patients National Kidney Foundation

We’re excited to share that the first patient has been treated in the Phase I/II trial of REJUVXL™️ cell therapy for Sta...
05/21/2025

We’re excited to share that the first patient has been treated in the Phase I/II trial of REJUVXL™️ cell therapy for Stage 3 CKD at the University of Miami. Huge thanks to Dr. Yelena Drexler, Dr. Alessia Fornoni, and the whole clinical team for making this milestone possible. Learn more here:

https://lnkd.in/dRWEbMxE



The study (NCT06721143), now underway at the University of Miami Health System, is progressing as planned in its evaluation of safety, tolerability, and early efficacy signals of AION Healthspan’s investigational cell therapy.
“This is an exciting and meaningful step in advancing this cell therapy approach to treating chronic kidney disease,” said Dr. Yelena Drexler, Principal Investigator on the CKD trial. “The successful completion of the investigational infusions for our first patient demonstrates our commitment to providing innovative therapies and paves the way for further critical observations and data collection. We are encouraged by the momentum and the support from both our patients and clinical team.”
AION Healthspan’s investigational therapy targets inflammation and fibrosis, the core drivers of kidney damage in CKD, with the goal of preserving or restoring renal function before the disease advances to dialysis or transplant.
“With the global rise in the prevalence of kidney disease, and the associated mortality rates often worse than the rates seen in oncology, the need for regenerative, disease-modifying treatments is urgent,” said Dr. Alessia Fornoni, nephrologist and member of AION’s Scientific Advisory Board. “We believe this approach, if successful, could represent a fundamental shift for CKD management.”

05/21/2025

AION Healthspan webpage is live @ www.AIONHealthspan.com
… and on LinkedIn: AION Healthspan, Inc.

Address

550 Bay Point Road
Miami, FL
33137

Telephone

+13055827151

Website

Alerts

Be the first to know and let us send you an email when AION Healthspan, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to AION Healthspan, Inc.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category